We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Diaceutics strikes two new enterprise-wide agreements

Thu 16 May 2024 10:09 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Technology and solutions provider Diaceutics has struck two new enterprise-wide agreements, taking the total number to six engagements, across 29 separate therapeutic brands.

Diaceutics said on Thursday that these enterprise-wide engagements demonstrated the "successful execution" of its strategy to offer more products and services to existing customers.

Enterprise-wide engagements currently represent annual recurring revenues of 9.0m, 2.5m of which relates to the two additional engagements announced today, making up "a significant proportion of group ARR".

The AIM-listed group added that in addition to the two new engagements announced today, its largest existing enterprise-wide customer had recently extended the term of its enterprise-wide engagement through the end of 2026.

Chief executive Ryan Keeling said: "The strength of our growing pipeline of new enterprise-level contracts highlights the progress we are making in becoming the primary commercialisation partner for pharma and biotech companies launching new precision medicines, validating the accelerated investment in our platform technology.

"These new engagements represent a significant step forward towards our core mission of getting every eligible patient the right test and the right therapy to positively impact their disease outcome."

As of 1000 BST, Diaceutics shares were up 4.33% at 108.50p.

Reporting by Iain Gilbert at Sharecast.com

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More AIM news from ShareCast

    No results were found